Sentinel Insight
- State
- CONFIRMED
- Impact
- HIGH
- Metric
- Major Pharma investment in non-hallucinogenic psychedelics
Psilocybin Alpha
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
Analysis News News Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C 18 August 2026 Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round at a $190M pre-money valuation, according to documents
Get email alerts when mushroom laws change in your area.
Email AlertsMerchants: Add legal status to your store →
Verified vendor: MIT45 — 10% off with code
Shop official siteMUSHROOMBANSAffiliate relationships do not influence legislative reporting.